Loading...
Immuno-oncology Setbacks And Cash Burn Will Block Progress Despite Promise
n/a
n/a
AnalystLowTarget's Fair Value
n/a
1Y
-65.6%7D
-14.8%1Y
-65.6%7D
-14.8%You can edit this narrative until Aug 12 10:51 PM. Then, changes will post as Updates.